CSIMarket


Generation Bio Co   (GBIO)
Other Ticker:  
 


 

Generation Bio Co

GBIO's Financial Statements and Analysis



Generation Bio Co narrowed forth quarter of 2023 net loss per share of $-0.48 compare to net loss per share of $-0.53 recorded in the same quarter a year ago a decrease compare to $-0.43 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.48 $  3 Mill
$+0.05     $+3M    



Generation Bio Co 's Revenue rose by 0 % in forth quarter of 2023 (Dec 31 2023) year on year, to $3 million and advanced by 34.11 % sequentially.


Generation Bio Co is

More on GBIO's Income Statement



Generation Bio Co 's in theforth quarter of 2023 recorded net loss of $-35.186 million, an increase from net loss of $-32.405 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on GBIO's Growth

Generation Bio Co Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-27 million, capital expenditures fell by -0.682571.55%, to $-5 millions compare to same quarter a year ago

More on GBIO's Cash flow Statement


Generation Bio Co does not pay out common stock dividend.

In trailing twelve-month period Generation Bio Co payed $ -0.82 cash per share, on a free-cash flow basis .

Book value fell by -10.61 % sequentially to $3.14 per share, -19.53% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.14 per share from $ 3.52.

Company repurchased 1.33 million shares or 2.02 % in Dec 31 2023.


More on GBIO's Dividends

 Market Capitalization (Millions) 205
 Shares Outstanding (Millions) 65
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -127
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) -7
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 174




Generation Bio Co does not pay out common stock dividend.

In trailing twelve-month period Generation Bio Co had negative $ -0.82 cash flow per share, on a free-cash flow basis .

Book value fell by -10.61 % sequentially to $3.14 per share, -19.53% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.14 per share from $ 3.52.

Company repurchased 1.33 million shares or 2.02 % in Dec 31 2023.


More on GBIO's Balance Sheets

 Market Capitalization (Millions) 205
 Shares Outstanding (Millions) 65
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -127
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) -7
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 174
   


  News about Generation Bio Co Earnings

Generation Bio Co Boasts Quarter 4 Revenue of $2.878 Million- Stay Informed on the Latest Earnings Results

The stock market is always filled with ups and downs, and it is crucial for investors to stay updated with the latest developments. In recent news, the Major Pharmaceutical Preparations company has showcased promising results in the fourth quarter of 2023. With a revenue of $2.878 million, the company has successfully demonstrated its ability to generate substantial income.
Additionally, Generation Bio Co, a significant player in the industry, reported a net loss of $-35.186 million for the same quarter. Although this figure is higher than the previous year's loss of $-32.405 million, it is essential to consider the context. The build-up in accounts receivable suggests a rising demand, indicating positiv...

Generation Bio Co. Achieves Outstanding Revenue of $2.146 Million in Q3 of Fiscal Year 2023

Generation Bio Co, a leading biotechnology company, has recently announced its financial results for the third quarter of the 2023 earnings season. The company reported a revenue of $2.146 million during this period, showcasing its strong market presence and positive performance.
However, it is important to note that Generation Bio Co also reported a net deficit of $-28.266 million in the third quarter of 2023 earnings season. Although this may seem concerning, it is worth mentioning that this deficit is actually an improvement compared to the deficit of $-31.306 million in the same reporting period last year. This indicates that the company has been able to reduce its losses and move towards a more stab...

Generation Bio Co Reports $0.88 Million Revenue for Recent Fiscal Period Ending June 2023

Financial News Report:
In the fiscal span ending June 30, 2023, the Major Pharmaceutical Preparations company reported a revenue of $0.88 mil...

Promising Growth: Generation Bio Co Reportedly Reduces Operating Deficit in First Quarter Fiscal 2023

Generation Bio Co is a biotechnology company that is currently gaining momentum in the pharmaceutical sector. The company is dedicated to developing cutting-edge genetic therapies that can revolutionize the way diseases are treated and cured. Although the company has yet to generate any revenue, shareholders are closely monitoring the company's progress as evidenced by its recent financial reports.
During the first quarter of 2023, Generation Bio Co's operating deficit came in at $-34.866 million, which has improved from the same period last year. The company has been able to mitigate some of its losses, as the diminishing returns have been trimmed from the period one year ago. This is a positive develop...


Date modified: 2024-03-08T05:42:50+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com